A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from LumiraDx, which recently went ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback